The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SLDB | +0.54% | -90.13% | -37.03% | -98% |
| S&P | +16.9% | +95.99% | +14.39% | +136% |
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.
Shareholders are expecting to finally get good news.
Investors appear to be skeptical about the biotech's latest clinical update.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.39M | 68.7% |
| Market Cap | $377.50M | 73.5% |
| Market Cap / Employee | $3.78M | 0.0% |
| Employees | 100 | 13.6% |
| Net Income | -$39.48M | -57.5% |
| EBITDA | -$41.31M | -55.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $138.93M | 44.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $20.16M | -12.6% |
| Short Term Debt | $2.90M | 28.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -57.15% | -15.5% |
| Return On Invested Capital | -55.74% | 11.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$37.79M | -73.7% |
| Operating Free Cash Flow | -$37.41M | -74.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.39 | 0.93 | 1.09 | 1.28 | 25.89% |
| Price to Tangible Book Value | 1.39 | 0.93 | 1.09 | 1.28 | 25.89% |
| Enterprise Value to EBITDA | -4.10 | -1.17 | 0.95 | -5.17 | 104.35% |
| Return on Equity | -65.8% | -94.6% | -55.3% | -68.2% | 34.32% |
| Total Debt | $24.72M | $24.18M | $23.63M | $23.05M | -8.88% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
